NKTX is expected to report earnings to rise 1.92% to -39 cents per share on March 20
Q4'24
Est.
$-0.40
Q3'24
Missed
by $0.02
Q2'24
Beat
by $0.13
Q1'24
Missed
by $0.03
Q4'23
Beat
by $0.01
The last earnings report on November 07 showed earnings per share of -38 cents, missing the estimate of -37 cents. With 1.92M shares outstanding, the current market capitalization sits at 167.25M.
a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer